Zastaprazan - Misplaced Pages

Pharmaceutical compound

Zastaprazan
Clinical data

Trade names	Jaqbo
Other names	JP-1366
Legal status
Legal status	Rx in South Korea
Identifiers
IUPAC name azetidin-1-yl--2,3-dimethylimidazopyridin-6-yl]methanone
CAS Number	2133852-18-1
PubChem CID	138622158
ChemSpider	115007138
UNII	W9S9KZX5MD
Chemical and physical data
Formula	C₂₂H₂₆N₄O
Molar mass	362.477 g·mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4
InChI InChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3 Key:FEQFUBYYZYQTOJ-UHFFFAOYSA-N

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker. In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.

References

Yang E, Hwang I, Ji SC, Kim J, Lee S (December 2024). "Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers". CPT. 13 (12): 2150–2158. doi:10.1002/psp4.13228. PMC 11646930. PMID 39268835.
Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC (September 2024). "Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease". Expert Opinion on Drug Metabolism & Toxicology: 1–16. doi:10.1080/17425255.2024.2397433. PMID 39189409.
Blair HA (July 2024). "Zastaprazan: First Approval". Drugs. 84 (7): 863–866. doi:10.1007/s40265-024-02057-w. PMID 38916840.
"Zastaprazan". AdisInsight. Springer Nature Switzerland AG.

v t e Drugs for peptic ulcer and GERD/GORD (A02B)
H₂ antagonists ("-tidine")	Cimetidine Famotidine Lafutidine Lavoltidine (loxtidine) Niperotidine Nizatidine Ranitidine Roxatidine
Prostaglandins (E)/ analogues ("-prost-")	Misoprostol Enprostil
Proton-pump inhibitors ("-prazole")	Azeloprazole Dexlansoprazole Dexrabeprazole Esomeprazole Ilaprazole Lansoprazole Omeprazole Pantoprazole Picoprazole Rabeprazole Tenatoprazole Timoprazole
Potassium-competitive acid blockers ("-prazan")	Fexuprazan Linaprazan Revaprazan Soraprazan Tegoprazan Vonoprazan Zastaprazan
Others	Aceglutamide aluminum Acetoxolone Alginic acid Arbaclofen placarbil Bismuth subcitrate Carbenoxolone Cetraxate Gefarnate Irsogladine Lesogaberan Pirenzepine Proglumide Rebamipide Sucralfate Sulglicotide Telenzepine Teprenone Troxipide Zinc L-carnosine Zolimidine
Combinations	Bismuth subcitrate/metronidazole/tetracycline Omeprazole/amoxicillin/rifabutin Vonoprazan/amoxicillin Vonoprazan/amoxicillin/clarithromycin
See also: Helicobacter pylori* eradication protocols*
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.